Aethlon Medical Appoints Robert S. Stefanovich as Chief Financial Officer.

Business Editors/Health & Medical Writers

SAN DIEGO--(BW HealthWire)--Oct. 31, 2001

Aethlon Medical Inc. (OTCBB:AEMD) announced today that Robert S. Stefanovich has been appointed as vice president and chief financial officer, reporting to James A. Joyce, the company's chairman, president and CEO.

"Robert is a welcome addition to the Aethlon team," said Joyce. "His level of expertise and global prospective are certainly rare, and his passion in supporting our causes is evident."

Stefanovich comes to Aethlon with more than 9 years of continuously growing responsibility for financial and administrative matters in start-up and Fortune 500 hi-tech companies. Prior to his appointment as chief financial officer of Aethlon, he has served as vice president for administration at Science Applications International Corp. (SAIC) and was the SEC reporting manager for Raychem Corp. (acquired by Tyco International Ltd.). Stefanovich has spent over five years in public accounting and was a member of the Software Advisory Group and Audit Manager with Price Waterhouse LLP's (now PricewaterhouseCoopers) Hi-tech practice in San Jose, Calif. His clients included Applied Biosystems, Hotmail, Larscom, Quester Technology, and TIBCO. Having lived and worked in Europe and Japan, he also brings extensive international experience to the company. Stefanovich holds a degree in business administration and mechanical engineering from the Technische Universitaet Darmstadt, Germany.

"I am very excited to be joining the Aethlon team," said Stefanovich. "While working as a consultant for Aethlon for the past months, I had the opportunity to meet and work with an experienced management team and board of directors. The company's sound strategic approach in developing new treatments for AIDS and Hepatitis-C has convinced me of the Company's great potential for future success."

Aethlon Medical is a development stage company that is expanding the applications of a novel, global therapeutic approach for treating HIV/AIDS and other epidemic diseases. The company's platform technology, known as the Hemopurifier(TM), is designed to rapidly reduce the presence of viruses and other intoxicants in the blood. The near term business strategy is to develop new therapies and standards of care for infectious diseases in two major revenue sectors, HIV/AIDS and Hepatitis-C (HCV).

Aethlon Medical's lead product candidates, AEMD-45 and AEMD-61, are positioned to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, decrease treatment resistance, and protect immune functions. Pre-clinical trials of AEMD-45 consistently document a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one overnight treatment. For more information on Aethlon Medical Inc., visit the company's Web site at www.AethlonMedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.